Frequency of adverse events following Q fever immunisation in young adults

Emily Sellens, Katrina L. Bosward, Susan Willis, Jane Heller, Rowland Cobbold, Jeannette L. Comeau, Jacqueline M. Norris, Navneet K. Dhand, Nicholas Wood

Research output: Contribution to journalArticle

Abstract

Q fever is a zoonosis of concern in many countries. Vaccination is the most effective means of prevention, and since 1989, Australia has had a licensed Q fever vaccine, Q-VAX®. This vaccine was also used in the Netherlands in 2011 following the largest recorded Q fever outbreak globally. There is a paucity of available data regarding adverse events following immunisation (AEFI) for young adult females. Such data are important for informing future vaccination recommendations both within Australia and internationally. This study collected Q fever vaccine (Q-VAX®) AEFI data in veterinary and animal science students at Australian universities. Students were enrolled at the time of vaccination and were emailed a link to an online AEFI survey one week later. Of the 60% (499/827) that responded, 85% were female and the median age was 18 years. Local injection site reactions (ISRs) occurred in 98% (95%; CI 96–99%) of respondents, of which 30% (95% CI 24–32%) were severe. Systemic AEFI occurred in 60% (95%; CI 55–64%) of respondents within the seven days following immunisation. Medical attention was sought by 19/499 (3.8%) respondents, of whom one sought treatment at a hospital emergency department. Females were more likely than males to experience any local ISR (odds ratio [OR] 9.3; 95% CI 2.5–33.8; p < 0.001), ISRs of greater severity (OR 2.5; 95% CI 1.5–4.2; p < 0.001), and any systemic AEFI (OR 1.9; 95% CI 1.1–3.1; p = 0.016). These safety data suggest that a high frequency of adverse events following immunisation should be expected in young adults, particularly females. However, the consequences of Q fever disease are potentially far more debilitating.
Original languageEnglish
Article number83
Pages (from-to)1-13
Number of pages13
JournalVaccines
Volume6
Issue number4
DOIs
Publication statusPublished - 13 Dec 2018

Fingerprint

Q Fever
Young Adult
Immunization
Vaccination
Vaccines
Odds Ratio
Injections
Students
Hospital Departments
Zoonoses
Netherlands
Disease Outbreaks
Hospital Emergency Service
Safety
Surveys and Questionnaires

Cite this

Sellens, E., Bosward, K. L., Willis, S., Heller, J., Cobbold, R., Comeau, J. L., ... Wood, N. (2018). Frequency of adverse events following Q fever immunisation in young adults. Vaccines, 6(4), 1-13. [83]. https://doi.org/10.3390/vaccines6040083
Sellens, Emily ; Bosward, Katrina L. ; Willis, Susan ; Heller, Jane ; Cobbold, Rowland ; Comeau, Jeannette L. ; Norris, Jacqueline M. ; Dhand, Navneet K. ; Wood, Nicholas. / Frequency of adverse events following Q fever immunisation in young adults. In: Vaccines. 2018 ; Vol. 6, No. 4. pp. 1-13.
@article{e67b714d9db3498ebb45ffde4fef792d,
title = "Frequency of adverse events following Q fever immunisation in young adults",
abstract = "Q fever is a zoonosis of concern in many countries. Vaccination is the most effective means of prevention, and since 1989, Australia has had a licensed Q fever vaccine, Q-VAX{\circledR}. This vaccine was also used in the Netherlands in 2011 following the largest recorded Q fever outbreak globally. There is a paucity of available data regarding adverse events following immunisation (AEFI) for young adult females. Such data are important for informing future vaccination recommendations both within Australia and internationally. This study collected Q fever vaccine (Q-VAX{\circledR}) AEFI data in veterinary and animal science students at Australian universities. Students were enrolled at the time of vaccination and were emailed a link to an online AEFI survey one week later. Of the 60{\%} (499/827) that responded, 85{\%} were female and the median age was 18 years. Local injection site reactions (ISRs) occurred in 98{\%} (95{\%}; CI 96–99{\%}) of respondents, of which 30{\%} (95{\%} CI 24–32{\%}) were severe. Systemic AEFI occurred in 60{\%} (95{\%}; CI 55–64{\%}) of respondents within the seven days following immunisation. Medical attention was sought by 19/499 (3.8{\%}) respondents, of whom one sought treatment at a hospital emergency department. Females were more likely than males to experience any local ISR (odds ratio [OR] 9.3; 95{\%} CI 2.5–33.8; p < 0.001), ISRs of greater severity (OR 2.5; 95{\%} CI 1.5–4.2; p < 0.001), and any systemic AEFI (OR 1.9; 95{\%} CI 1.1–3.1; p = 0.016). These safety data suggest that a high frequency of adverse events following immunisation should be expected in young adults, particularly females. However, the consequences of Q fever disease are potentially far more debilitating.",
keywords = "Q fever vaccination, Adverse events, Coxiella burnetii",
author = "Emily Sellens and Bosward, {Katrina L.} and Susan Willis and Jane Heller and Rowland Cobbold and Comeau, {Jeannette L.} and Norris, {Jacqueline M.} and Dhand, {Navneet K.} and Nicholas Wood",
note = "Includes bibliographical references.",
year = "2018",
month = "12",
day = "13",
doi = "10.3390/vaccines6040083",
language = "English",
volume = "6",
pages = "1--13",
journal = "Vaccines",
issn = "2076-393X",
publisher = "Multidisciplinary Digital Publishing Institute",
number = "4",

}

Sellens, E, Bosward, KL, Willis, S, Heller, J, Cobbold, R, Comeau, JL, Norris, JM, Dhand, NK & Wood, N 2018, 'Frequency of adverse events following Q fever immunisation in young adults', Vaccines, vol. 6, no. 4, 83, pp. 1-13. https://doi.org/10.3390/vaccines6040083

Frequency of adverse events following Q fever immunisation in young adults. / Sellens, Emily; Bosward, Katrina L.; Willis, Susan; Heller, Jane; Cobbold, Rowland; Comeau, Jeannette L.; Norris, Jacqueline M.; Dhand, Navneet K.; Wood, Nicholas.

In: Vaccines, Vol. 6, No. 4, 83, 13.12.2018, p. 1-13.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Frequency of adverse events following Q fever immunisation in young adults

AU - Sellens, Emily

AU - Bosward, Katrina L.

AU - Willis, Susan

AU - Heller, Jane

AU - Cobbold, Rowland

AU - Comeau, Jeannette L.

AU - Norris, Jacqueline M.

AU - Dhand, Navneet K.

AU - Wood, Nicholas

N1 - Includes bibliographical references.

PY - 2018/12/13

Y1 - 2018/12/13

N2 - Q fever is a zoonosis of concern in many countries. Vaccination is the most effective means of prevention, and since 1989, Australia has had a licensed Q fever vaccine, Q-VAX®. This vaccine was also used in the Netherlands in 2011 following the largest recorded Q fever outbreak globally. There is a paucity of available data regarding adverse events following immunisation (AEFI) for young adult females. Such data are important for informing future vaccination recommendations both within Australia and internationally. This study collected Q fever vaccine (Q-VAX®) AEFI data in veterinary and animal science students at Australian universities. Students were enrolled at the time of vaccination and were emailed a link to an online AEFI survey one week later. Of the 60% (499/827) that responded, 85% were female and the median age was 18 years. Local injection site reactions (ISRs) occurred in 98% (95%; CI 96–99%) of respondents, of which 30% (95% CI 24–32%) were severe. Systemic AEFI occurred in 60% (95%; CI 55–64%) of respondents within the seven days following immunisation. Medical attention was sought by 19/499 (3.8%) respondents, of whom one sought treatment at a hospital emergency department. Females were more likely than males to experience any local ISR (odds ratio [OR] 9.3; 95% CI 2.5–33.8; p < 0.001), ISRs of greater severity (OR 2.5; 95% CI 1.5–4.2; p < 0.001), and any systemic AEFI (OR 1.9; 95% CI 1.1–3.1; p = 0.016). These safety data suggest that a high frequency of adverse events following immunisation should be expected in young adults, particularly females. However, the consequences of Q fever disease are potentially far more debilitating.

AB - Q fever is a zoonosis of concern in many countries. Vaccination is the most effective means of prevention, and since 1989, Australia has had a licensed Q fever vaccine, Q-VAX®. This vaccine was also used in the Netherlands in 2011 following the largest recorded Q fever outbreak globally. There is a paucity of available data regarding adverse events following immunisation (AEFI) for young adult females. Such data are important for informing future vaccination recommendations both within Australia and internationally. This study collected Q fever vaccine (Q-VAX®) AEFI data in veterinary and animal science students at Australian universities. Students were enrolled at the time of vaccination and were emailed a link to an online AEFI survey one week later. Of the 60% (499/827) that responded, 85% were female and the median age was 18 years. Local injection site reactions (ISRs) occurred in 98% (95%; CI 96–99%) of respondents, of which 30% (95% CI 24–32%) were severe. Systemic AEFI occurred in 60% (95%; CI 55–64%) of respondents within the seven days following immunisation. Medical attention was sought by 19/499 (3.8%) respondents, of whom one sought treatment at a hospital emergency department. Females were more likely than males to experience any local ISR (odds ratio [OR] 9.3; 95% CI 2.5–33.8; p < 0.001), ISRs of greater severity (OR 2.5; 95% CI 1.5–4.2; p < 0.001), and any systemic AEFI (OR 1.9; 95% CI 1.1–3.1; p = 0.016). These safety data suggest that a high frequency of adverse events following immunisation should be expected in young adults, particularly females. However, the consequences of Q fever disease are potentially far more debilitating.

KW - Q fever vaccination

KW - Adverse events

KW - Coxiella burnetii

UR - http://www.scopus.com/inward/record.url?scp=85062341387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062341387&partnerID=8YFLogxK

U2 - 10.3390/vaccines6040083

DO - 10.3390/vaccines6040083

M3 - Article

VL - 6

SP - 1

EP - 13

JO - Vaccines

JF - Vaccines

SN - 2076-393X

IS - 4

M1 - 83

ER -

Sellens E, Bosward KL, Willis S, Heller J, Cobbold R, Comeau JL et al. Frequency of adverse events following Q fever immunisation in young adults. Vaccines. 2018 Dec 13;6(4):1-13. 83. https://doi.org/10.3390/vaccines6040083